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Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is linked to the deletion of the D4Z4 arrays at chromosome 4q35. Recent
studies suggested that aberrant expression of double homeobox 4 (DUX4) from the last D4Z4 repeat causes FSHD. The aim
of this study is to determine transcriptomic responses to ectopically expressed DUX4 in human and mouse cells of muscle
lineage. We expression profiled human rhabdomyosarcoma (RD) cells and mouse C2C12 cells transfected with expression
vectors of DUX4 using the Affymetrix Human Genome U133 Plus 2.0 Arrays and Mouse Genome 430 2.0 Arrays, respectively.
A total of 2267 and 150 transcripts were identified to be differentially expressed in the RD and C2C12 cells, respectively.
Amongst the transcripts differentially expressed in the RD cells, MYOD and MYOG (2 fold, p,0.05), and six MYOD
downstream targets were up-regulated in RD but not C2C12 cells. Furthermore, 13 transcripts involved in germline function
were dramatically induced only in the RD cells expressing DUX4. The top 3 IPA canonical pathways affected by DUX4 were
different between the RD (inflammation, BMP signaling and NRF-2 mediated oxidative stress) and the C2C12 cells (p53
signaling, cell cycle regulation and cellular energy metabolism). Amongst the 40 transcripts shared by the RD and C2C12
cells, UTS2 was significantly induced by 76 fold and 224 fold in the RD and C2C12 cells, respectively. The differential
expression of MYOD, MYOG and UTS2 were validated using real-time quantitative RT-PCR. We further validated the
differentially expressed genes in immortalized FSHD myoblasts and showed up-regulation of MYOD, MYOG, ZSCAN4 and
UTS2. The results suggest that DUX4 regulates overlapped and distinct groups of genes and pathways in human and mouse
cells as evident by the selective up-regulation of genes involved in myogenesis and gametogenesis in human RD and
immortalized cells as well as the different molecular pathways identified in the cells.
Citation: Sharma V, Harafuji N, Belayew A, Chen Y-W (2013) DUX4 Differentially Regulates Transcriptomes of Human Rhabdomyosarcoma and Mouse C2C12
Cells. PLoS ONE 8(5): e64691. doi:10.1371/journal.pone.0064691
Editor: Brian P. Chadwick, Florida State University, United States of America
Received February 25, 2013; Accepted April 16, 2013; Published May 22, 2013
Copyright:  2013 Sharma et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Research reported in this publication was supported by the NIH/NIAMS under Award Number 1R01AR052027. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the National Institutes of Health. V.S and N. H. are supported by NIH/NIAMS1R01AR052027. Y-
W.C. is supported by NIH/NIAMS1R01AR052027, NIH/NICHD1R24HD050846 and DOD DOD W81XWH-10-1-0659. A.B.  acknowledges the Global FSHD Foundation
(Australia). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ychen@cnmcresearch.org
Introduction
FSHD is an autosomal dominant disorder and the third most
common inherited form of muscular dystrophy. The disease is
characterized by a progressive and selective weakness and atrophy
of the facial, scapular, and humeral muscles followed by weakness
of muscles of the lower extremities. The weakness of muscles is
often asymmetric. There are currently no pharmacologic therapies
available to treat this disease [1–4]. FSHD1 (OMIM #158900)
affects 95% of patients and is genetically linked to contractions of
the D4Z4 repeat array at chromosome 4q35 from 11–150 repeat
units in healthy individuals to 1–10 repeat units in patients with
FSHD. Individuals without any repeat do not develop FSHD [1–
4]. Each of the repeat units contains a conserved ORF for the
double homeobox 4 (DUX4) gene, which is aberrantly transcribed
from the last repeat in patients. FSHD2 (OMIM #158901) is not
linked to contractions of the D4Z4 repeat array but to mutations
in the SMCHD1 protein involved in chromatin structure [5].
DNA hypomethylation of the D4Z4 region is common to both
FSHD1 and 2 and causes transcriptional de-repression, which
allows the DUX4 gene to be transcribed. The FSHD permissive
alleles further present a poly-adenylation signal in the pLAM
region distal to the repeat array [6], which allows stabilization of
the DUX4 transcripts derived from the last D4Z4 unit and their
translation [6–14].
The DUX4 protein is a homeodomain transcription factor
[6,9]. The function of DUX4 has been primarily studied using
mice [15,16]. Previous studies showed that ectopic expression of
human DUX4 in C2C12 cells induced genes involved in oxidative
stress as well as suppressed MYOD pathways [15]. In addition,
ectopic DUX4 expression induced p53-dependant muscle cell
death both in vitro and in vivo [15,16]. While some of the findings in
these mouse studies agree with what has been reported in studies
of human muscle biopsies and myoblasts, including the involve-
ment of oxidative stress responses and cell apoptosis, others such as
suppression of MYOD signaling did not agree with findings using
patient samples [17–26]. Considering the differences between the
mouse and human studies, and the fact that there is no orthologue
of DUX4 in the mouse genome although two paralogues were
reported [8], it is critical to know whether the transcription
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regulatory targets of human DUX4 are the same in mouse cells.
The knowledge will allow us to determine whether DUX4-
regulated pathways can be properly studied in mouse models.
In this study, we compared transcriptomic changes that are
induced in response to ectopic DUX4 expression in human and
mouse cell lines of muscle lineage. Expression profiling studies of
human RD cells and mouse C2C12 cells transfected with DUX4
expression vectors were conducted. The C2C12 cell line is a
mouse myoblast cell line that derived from skeletal muscles of C3H
mice [27] and has since been commonly used to study cellular and
molecular pathways in muscle [6,15]. The human RD cell line is a
rhabdomyosarcoma cell line that was derived from a human
embryonal rhabdomyosarcoma [28]. This cell line expresses
myogenic markers and has been used extensively for studying
regulatory pathways in muscles [29,30]. In this study the mRNA
expression changes of the RD and C2C12 cells in response to
ectopic DUX4 expression was studied and compared. Considering
the RD cells are of neoplastic origin, we also validated our results
using immortalized human myoblasts from patients with FSHD.
Methods
Cell Culture and Transfection
The cell culture and transfection experiments of both the RD
from American Type Culture Collection (ATCC) and C2C12 cells
(ATCC) were conducted in parallel under the same conditions. A
total of 16105 cells were seeded and cultured to 60% confluence in
Dulbecco’s modified Eagle’s medium containing 10% heat
inactivated fetal bovine serum (Sigma-Aldrich) and 1% penicil-
lin-streptomycin in 25 cm2 flasks at 37uC, 5% CO2. The cells
were transfected with 6.25 mg pCIneo-DUX4 [9] expression
vector (n = 4) using Lipofectamine LTX (Life Technologies)
according to the manufacturer’s protocol, and cells collected
16 hours afterwards. Cells transfected with pCIneo insertless
vector were used as controls. Transfection efficiency was
determined using cells transfected with GFP expression vector.
Percentages of GFP positive cells of 5 random fields were
calculated and averaged. The transfection efficiency in C2C12
and RD cells were 91% (63%) and 89% (61%), respectively.
Immortalized human myoblasts were obtained from the Senator
Paul Wellstone Muscular Dystrophy Cooperative Research Center
at Boston Biomedical Research Institute. The patient myoblast cell
line was derived from the biceps of a 42 years old male with mild
muscle weakness (WS157) [31]. The control myoblasts were
derived from the patient’s 46 year old brother without FSHD
(WS161) [31]. These cells were immortalized with expression
vectors encoding hTERT that compensates for telomere loss and
CDK4 that prevents growth arrest of CD56+ myogenic cells,
when these cells are cultured in-vitro. We cultured these cells as
described in previously published protocol [31,32]. Briefly,
proliferating immortalized myoblasts were cultured in a growth
medium consisting of medium 199 and DMEM (Life Technolo-
gies) in a 1:4 ratio with 0.8 mM sodium pyruvate (Life
Technologies), 3.4 g/l sodium bicarbonate (Sigma-Aldrich), 15
% fetal bovine serum (Thermo Scientific), 0.03 mg/ml Zinc sulfate
(Fisher), 1.4 mg/ml vitamin B12 (Sigma-Aldrich), 2.5 ng/ml
recombinant human hepatocyte growth factor (Millipore),
10 ng/ml basic fibroblast growth factor (Biopioneer), 0.02 M
HEPES, and (Life Technologies) at 37uC, 5% CO2. The culture
dish was coated with 0.1 % gelatin (Sigma-Aldrich).
Expression Profiling and Data Analyses
Affymetrix Human Genome U133 Plus 2.0 and Mouse 430 Plus
2.0 arrays were used for profiling the RD and C2C12 cells,
respectively. The procedures were conducted as previously
described [6]. Briefly, total RNA was isolated from human RD
and mouse C2C12 cells using TRIzol (Invitrogen) according to the
manufacturer’s protocol and purified using the RNeasy MinElute
Cleanup Kit (Qiagen) according to the manufacturer’s protocol.
Four hundred nanograms of total RNA was converted into double
stranded cDNA, then biotin labeled cRNA, which was subse-
quently fragmented. All of the steps were performed using the
Affymetrix 39-IVT Express Kit. The fragmented cRNA was
hybridized to microarrays for 16 hours at 45uC. Following
hybridization, the washing and staining steps were performed
using Fluidics Station 450 as described in the Affymetrix protocol.
The probe arrays were subsequently scanned using the Genechip
Scanner 3000 to acquire images providing the raw data of gene
expression. The microarray data generated is deposited to the
Gene Expression Omnibus (GEO) database (accession number
GSE45854).
The raw data were imported into GeneSpring GX 11.0
software (Silicon Genetics, CA, USA) for filtering and statistical
analysis. The probe sets showing at least one Affymetrix ‘present’
calls out of a total of eight human or mouse arrays (,10% Present
calls), respectively, were selected for further statistical analysis.
Welch’s t test was performed to calculate the probabilities of
significant gene expression changes (p,0.05) along with multiple
testing correction using Benjamini Hochberg False Discovery Rate
(5%).
The gene lists generated in Genespring were imported into
Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood,
CA), which is a web based bioinformatics tool used to identify
canonical pathways differentially regulated in microarray datasets.
The significance of genes from the microarray data assigned to
pathways by IPA is determined by the ratio of the number of genes
in the dataset mapping to a specific pathway to the total number of
genes in the IPA database mapping to that pathway. Fischer’s
exact test was used to calculate a p-value that determines whether
the association between the gene and the pathway is significant.
The pathways are subsequently ranked according to the p-value.
Real-time Quantitative Reverse Transcription Polymerase
Chain Reaction (real-time qRT-PCR)
Real-time qRT-PCR was performed to validate microarray
results as previously described [6,33]. Briefly, total RNA (1 mg)
from each sample was first subjected to DNAse I digestion (1 U) in
16DNAse I reaction buffer (Promega) by incubating at 37uC for
30 minutes to remove genomic DNA contamination. The reaction
was inactivated by adding 1 ml of stop solution (Promega) and
heating for 10 minutes at 65uC. Subsequently, the RNA sample
was reverse transcribed to cDNA using Superscript II (Life
Technologies) and oligo dT primers. The cDNA thus generated
was amplified in triplicates in SYBR Green PCR Master Mix (Life
Technologies) using 1 mM of forward and reverse primers specific
to each gene and 1 ml of cDNA template in a total volume of
50 ml. The thermal cycling conditions included 50uC for 2 min,
95uC for 10 min, followed by 40 cycles of amplification using the
condition of 95uC for 15 s then 60uC for 1 min. Primer sequences
used for human myogenic differentiation 1 (MYOD) were (forward) 59 -
TGCTCCGACGGCATGATGGAC -39 and (reverse) 59-TCGA-
CACCGCCGCACTCT -39; urotensin 2 (UTS2) were (forward) 59-
AAGTTTCAGGATTTCTCTGGACAAGATCC -39 and (re-
verse) 59- CCAGAAGCAATCAGGAGTCTCACG-39; myogenin
(MYOG) (forward) were 59-AACCCAGGGGATCATCTGCT-
CAC-39 and (reverse) 59-GTTGGGCATGGTTTCATCTGG-
GAAG-39; zinc finger and SCAN domain containing 4 (ZSCAN4) were
(forward) 59-TGGAAATCAAGTGGCAAAAA-39 and (reverse)
Human and Mouse Transcriptomes Regulated by DUX4
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59-CTGCATGTGGACGTGGAC-39 [24]. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used as internal control and the
primers used were (forward) 59- TGTCAAGCT-
CATTTCCTGGTA-39 and (reverse) 59-
GTGAGGGTCTCTCTCTTCCTCTTGT-39. Primer sequences
used for mouse urotensin 2 (Uts2) were (forward) 59-GAG-
GAAGGCTTTCGCTGGGCA-39 and 59-
GGGCAGCCCCGTGTTGCTTA-39. Glyceraldehyde-3-phosphate
dehydrogenase (Gapdh) was used as internal control and the primers
used were (forward) 59-CCAGGAGCGAGACCCCACTAACA-
39 and (reverse) 59-TCAAGTGGGCCCCGGCCTT-39. All
primers were tested for nonspecific amplicons and primer dimers
by visualizing PCR products on 1% agarose gels as well as melting
curve analysis. The DDCT method was used to determine
expression values relative to GAPDH as well as fold differences
relative to insertless vector. T-test was used (P,0.05) to determine
statistical significance.
Results
DUX4 regulates distinct groups of transcripts in the RD
cells
To determine the molecular responses to ectopic expression of
DUX4 in human RD and mouse C2C12 cells, we expression
profiled human RD and mouse C2C12 cells transfected with
DUX4 expression vector. The cells were cultured and transfected
in parallel and same statistical criteria were applied when the array
data were analyzed. A total of 2267 transcripts were differentially
expressed in RD cells (Table S1), while 150 differentially expressed
transcripts were identified in C2C12 cells (Table S2). A total of 40
differentially expressed transcripts were shared between the two
cell lines (Table S3). Among the shared genes, the direction of
expression changes of the majority of the genes were the same
suggesting these responses were truly shared between the RD and
C2C12 cells. Molecular pathways affected by DUX4 in human
RD cells and mouse C2C12 cells were further examined using
Ingenuity Pathway Analysis (IPA). The results showed that top 3
canonical pathways affected by DUX4 expression in RD cells were
those involved in Wnt-mediated immune responses, BMP
signaling and NRF-2 mediated oxidative stress response, whereas
in C2C12 cells were those involved in p53 signaling, cell cycle
regulation, and cellular energy metabolism. The results showed
that the most significantly affected molecular pathways by DUX4
are distinct in the RD cells and C2C12 cells while some expression
changes were shared.
The Wnt-mediated inflammatory immune response pathway
was found to be the top ranked pathway affected by DUX4 in the
RD cells as evidenced by significant up-regulation of WNT5A (1.4
fold, p,0.05), and several frizzled family receptors, namely FZD1
(1.6 fold, p,0.01), FZD2 (1.5 fold, p,0.05), FZD4 (1.5 fold,
p,0.01), and FZD7c (1.6 fold, p,0.01) (Table S4). However, the
transcripts of interleukins IL6 (21.8 fold, p,0.05), IL8 (22.2 fold,
p,0.01), and IL15 (21.4 fold, p,0.05), which are downstream of
WNT5A were down-regulated.
The BMP signaling pathway was found to be the second ranked
pathway. Of the 39 transcripts that belong to this pathway in the
IPA database, 17 transcripts were misregulated in response to
ectopic DUX4 expression in the RD cells. Amongst the
misregulated transcripts, 53% of the expression changes were
shown to be involved in suppression of the BMP signaling pathway
while 35% of the changes indicated activation of the pathway
(Table S5).
The NRF-2 mediated oxidative stress response pathway was
identified to be the third ranked pathway regulated by DUX4 in
the RD cells. Thirty one of the 86 transcripts known to function in
this pathway were found to be misregulated in this study. Among
the 31 differentially expressed transcripts, 55% of the changes may
potentially induce or contribute to oxidative stress, while 39% of
them were reported to be involved in anti-oxidative stress
responses (Table S6).
DUX4 significantly up-regulated genes involved in
myogenesis and gametogenesis in the RD cells but not
C2C12 cells
Since myogenesis factors and genes regulating cell cycle have
previously been reported to be affected in primary FSHD
myoblasts [19,21,26], we first looked up the expression changes
of two major myogenic factors, MYOD and MYOG, in the profiling
data. The results showed that MYOD (Figure 1A) and MYOG
(Figure 1B) were 2 fold up-regulated in the RD cells (p,0.05) but
not in the C2C12 cells ectopically expressing DUX4. Six
transcripts reported as direct targets of MYOD, namely BIN1
(1.4 fold, p,0.05), HMGB3 (1.3 fold, p,0.05), SIX1 (1.5 fold,
p,0.05), ACTC1 (1.3 fold, p,0.05), IGFBP5 (1.5 fold, p,0.05),
and CHRNA1 (2.1 fold, p,0.05) [34], were also up-regulated only
in the RD cells transfected with the DUX4 expression vector. In
addition, several transcripts involved in cell cycle progression were
shown down-regulated in the RD cells, including CCND1 (21.3
fold, p,0.05), CCND2 (21.3 fold, p,0.05), CDC6 (21.3 fold,
p,0.01) and E2F7 (21.5-fold, p,0.05) but not in the C2C12
cells. To validate the significant up-regulation of MYOD and
MYOG in the RD cells, we performed real-time qRT-PCR and
confirmed that both MYOD (20 fold, p,0.05) and MYOG (12 fold,
p,0.05) were up-regulated in the RD cells ectopically expressing
DUX4 (Figure 1C–D).
A small number of genes showed dramatic up-regulation
(.100-fold) only in the RD cells ectopically expressing DUX4,
which formed a cluster of transcripts (Figure 2A–B). These
transcripts were MBD3L2 (2805 fold, p,0.01), TRIM43 (2060
fold, p,0.01), ZSCAN4 (1546 fold, p,0.01), RFPL1/RFPL2 (1231
fold, p,0.01), PRAMEF1/PRAMEF13/PRAMEF2 (1217 fold,
p,0.01), PRAMEF12 (711 fold, p,0.01), TRIM48 (421 fold,
p,0.01), TRIM49 (409 fold, p,0.05), RFPL2 (332 fold, p,0.01),
KHDC1L (254 fold, p,0.01), RFPL3 (204 fold, p,0.01), SPRYD5
(171 fold, p,0.01), and PRAMEF11 (126 fold, p,0.01). Out of
these, only Zscan4 was up-regulated (7.4 fold, p,0.01) in C2C12
cells ectopically expressing DUX4. While not expressing in normal
skeletal muscle, these transcripts are expressed in germ cells,
embryos during preimplantation and early embryogenesis. The
genes were also reported to be up-regulated in immortalized
human myoblasts ectopically expressing DUX4 [20].
DUX4 induced up-regulation of UTS2 in both the RD and
C2C12 cells ectopically expressing DUX4
While the majority of the genes induced by DUX4 expression in
RD and C2C12 cells were cell-specific, 40 transcripts were
similarly regulated by DUX4 in both cell lines suggesting there are
shared transcriptional targets in the cells (Table S3) and urotensin-
2 (UTS2) was one of them. UTS2 was significantly up-regulated in
the RD cells (76 fold, p,0.01) and C2C12 cells (224 fold, p,0.01)
ectopically expressing DUX4 (Figures 3A–B). The finding were
validated by real-time qRT-PCR in both the RD and C2C12 cells
with fold changes of 130 fold (p,0.01) and 21 fold (p,0.05)
respectively (Figure 3C–D).
Human and Mouse Transcriptomes Regulated by DUX4
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e64691
Figure 1. Up-regulation of MYOD and MYOG in response to ectopic DUX4 expression in RD cells. Expression levels of myogenic markers
MYOD (A) and MYOG (B) were determined by expression profiling human RD cells transfected with an expression vector either encoding DUX4 or
insertless (control), respectively. The differential expression of MYOD (C) and MYOG (D) were validated using real-time qRT-PCR (n = 4). Normalized
expression levels of the transcripts were calculated using GAPDH as a reference. ** p,0.01, * p ,0.05.
doi:10.1371/journal.pone.0064691.g001
Figure 2. Scatter plot analysis of transcripts regulated by ectopically expressed DUX4 in RD and C2C12 cells. To clearly visualize
transcripts highly induced by DUX4, only transcripts changed .2-fold were used for analysis. Log transformed expression levels of transcripts in cells
transfected with the insertless vector was plotted against expression levels of transcripts in cells transfected with the DUX4 expression vector. A
cluster of transcripts highly induced by DUX4 (circled) in RD (A.) but not C2C12 cells (B.) was observed.
doi:10.1371/journal.pone.0064691.g002
Human and Mouse Transcriptomes Regulated by DUX4
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Transcripts upregulated by ectopic DUX4 expression
were upregulated in immortalized FSHD myoblasts
To determine whether the expression changes identified in the
RD cells ectopically expressing DUX4 can be detected in the
FSHD myoblasts, we performed real-time qRT-PCR and
validated the significant up-regulation of MYOD (19 fold,
p,0.01), MYOG (110 fold, p,0.01), ZSCAN4 (32 fold, p,0.01),
and UTS2 (229 fold, p,0.01) (Figure 4A–D) in immortalized
FSHD cells as compared to the control immortalized myoblasts.
Discussion
Misregulation of genes and pathways involved in myogenesis,
cell cycle regulation and oxidative stress in human FSHD
myoblasts has been reported previously [13–23]. Recently genes
involved in gametogenesis were shown to be up-regulated in
immortalized FSHD myoblasts and muscle biopsies [20,35,36].
While some of the changes were also reported in studies conducted
using C2C12 cells and animal models, such as increased
susceptibility to oxidative stress and the induction of cell death,
other findings did not agree with the human studies including how
the myogenesis program was affected by DUX4 and the induction
of the germline genes [15,16,35,36]. To further investigate the
genes and pathways regulated by DUX4 in human and mouse
cells of muscle lineage, we analyzed mRNA transcripts affected by
ectopically expressed DUX4 using expression profiling. Our
results showed that while the RD cells expressing DUX4
recapitulated the molecular defects seen in human muscles and
immortalized myoblasts, the C2C12 cells responded differently to
the DUX4 expression. For example, the most dramatic expression
changes of the germline genes were induced by DUX4 in both RD
and immortalized FSHD myoblasts and observed in patients’
muscles but not the C2C12 cells. Among these genes, only
ZSCAN4 was mildly up-regulated in the C2C12 cells. In general,
DUX4 regulated significantly greater number of genes (2267) in
RD cells as compared with C2C12 cells (150) suggesting that
DUX4 may have more direct regulatory targets in RD cells as
compared with C2C12 cells. In addition, several pathways and
genes previously reported to be misregulated in FSHD were shown
affected in the RD cells but not in the C2C12 cells. The similarity
among the human RD cells, the immortalized FSHD myoblasts
and the primary myoblasts suggest that RD and immortalized
Figure 3. Up-regulation of human UTS2 and mouse Uts2 was observed in RD and C2C12 cells ectopically expressing DUX4,
respectively. Expression levels of human UTS2 and mouse Uts2 were determined by expression profiling RD (A) and C2C12 (B) cells transfected with
an expression vector either encoding DUX4 or insertless (control), respectively. The expression changes in RD (C) and C2C12 (D) were validated using
real-time qRT-PCR (n = 4). Normalized expression levels of the transcripts were calculated using GAPDH and Gapdh as a reference in both cell lines. **
p,0.01, * p ,0.05.
doi:10.1371/journal.pone.0064691.g003
Human and Mouse Transcriptomes Regulated by DUX4
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FHSD myoblasts may be more suitable culture systems for
studying DUX4 function than mouse C2C12 cells. Whether
mouse or other animal models that carry human DUX4 in their
genomes can be used to study DUX4 function or can be a suitable
FSHD disease model need to be further investigated.
Previous studies showed up-regulation of MYOD and its
downstream regulatory targets accompanied by a halt in cell
cycle progression in human myoblasts and biopsies therefore a
hypothesis that pre-mature activation of myogenesis program was
involved in the pathological mechanisms of FSHD was proposed
[19,21,26]. MYOD is a transcription factor that activates
myogenesis through regulation of several transcriptional targets
that facilitates the transformation of quiescent satellite cells (stem
cells committed to muscle lineage) into proliferating myoblasts
which are capable of undergoing differentiation [37]. While the
activated myoblasts are essential for muscle maintenance and
repair, maintaining a healthy number of satellite cells is critical for
a continuous supply of myoblasts [38]. A pre-mature activation of
myogenesis induced by DUX4 bares a risk to prematurely deplete
satellite cells, which can potentially lead to diminished regener-
ative capacity of the adult skeletal muscle. Our profiling and real-
time qRT-PCR data showed up-regulation of MYOD and MYOG
as well as suppression of cell cycle progression in the RD cells
expressing DUX4. The up-regulation of MYOD and MYOG was
further validated using immortalized FHSD myoblasts. The
findings are in concordance with previous studies in primary
FSHD myoblasts and muscle biopsies [19,21,26]. Our data
provide a direct link between DUX4 expression and the activation
of myogenesis program as evidenced by activation of MYOD and
its downstream target genes accompanied by a halt in cell cycle
progression, a critical step prior to differentiation.
A recent study by Geng et al [20] showed activation of MYOG
expression in response to ectopic expression of DUX4 in human
immortalized myoblasts, which is consistent with activation of
MYOD signaling since terminal differentiation involves increased
MYOG and decreased MYOD expression levels, a step necessary
for myoblasts to fuse and form mature myofibers [39,40]. Since
our results showed higher expression levels of both MYOD and
MYOG by DUX4 overexpression, this indicates these cells are at
an earlier stage of differentiation process. This could be explained
by the fact that our study was conducted at an earlier time point
(16 hours post-transfection) as compared to the study conducted
by Geng et al (24 hours post-transfection). While the studies
conducted using human muscle biopsies and myoblasts reported
activation of MYOD pathways [19,21,26], studies conducted in
C2C12 cells reported repression of MYOD pathways in response
to ectopically expressed DUX4 as well as DUX4c [15,41] The
different conclusions from human and mouse studies can
potentially be explained by the lack of DUX4 orthologue in mice;
therefore human DUX4 does not regulate Myod and other
regulatory target genes the same way.
In addition to activation of MYOD program, we also identified
a suppression of BMP signaling pathways in RD cells expressing
DUX4. The BMP pathways negatively regulate MYOD program
and was identified as the second top ranked pathway in the RD
cells ectopically expressing DUX4. BMP signaling has been shown
Figure 4. Up-regulation of MYOD, MYOG, ZSCAN4, and UTS2 in FSHD immortalized cells. MYOD (A.), MYOG (B.), ZSCAN4 (C.), and UTS2 (D.)
levels were quantified in FSHD immortalized cells and control cells using real-time qRT-PCR (n = 4). Values representing expression levels of transcripts
were calculated using GAPDH as a reference. ** p,0.01.
doi:10.1371/journal.pone.0064691.g004
Human and Mouse Transcriptomes Regulated by DUX4
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to be activated during the proliferation stage of satellite cells. The
BMP signaling is suppressed during differentiation by a BMP
antagonist Noggin [42]. Our profiling data suggested a suppres-
sion of the BMP signaling with the BMP antagonist Noggin up-
regulated by DUX4 (1.6 fold, p,0.05; Table S5). Overall, the
data support our conclusions that DUX4 expression leads to
induction of myogenesis through activation of MYOD signaling
and increased expression of Noggin.
The top ranked pathway identified by IPA to be differentially
regulated in RD cells ectopically expressing DUX4 are genes
involved in innate immune response as evidenced by up-regulation
of WNT5A, and several FZD receptors. Genomic studies have
shownWNT5A, agonist of FZD receptors, to be up-regulated in T-
cells, macrophages and dendritic cells exposed to pathogens as well
as in pathologies involving inflammation such as rheumatoid
arthritis. Previous studies suggest that Wnt5A is a positive
regulator of immunity and inflammation [43–47]. Our data
therefore indicate that DUX4 directly induces an inflammatory
immune response, which could contribute to the T-cell mediated
inflammation in FSHD reported previously [35,48]. Interestingly,
some interleukin genes functioning in lymphocyte activation and
infiltration downstream of Wnt5A are downregulated in our RD
data suggesting compensatory mechanisms to combat Wnt5A
signaling. However, while WNT5A can be involved in regulating
immune responses, it is also highly expressed in satellite cells and is
involved in switching cells from proliferation to myogenic
differentiation [49]. The up-regulation of Wnt signaling in the
myoblasts can potentially contribute to increased myogenesis and
not related to inflammation.
The top ranked pathway affected by DUX4 expression in the
C2C12 cells was the p53 pathway. P53 signaling has been shown
to be activated by DUX4 in mice ectopically expressing DUX4 in
vivo and other animal models expressing DUX4 [16,50]. In
addition, it is shown to be up-regulated in human FSHD
myoblasts during differentiation [24]. This pathway was also
highly ranked among the pathways affected in the RD cells
expressing DUX4 but not in the top 3. It should be noted that RD
cells are of neoplastic origin and contain point mutations in the
tumor suppressing p53 gene leading to its functional loss [51–53].
This could potentially explain the reasons for the p53 pathway not
being amongst the top 3 ranked affected pathway by DUX4 in RD
cells. While the activation of the p53 pathway was suggested based
on the IPA, we did not observe obvious reduction of total cell
numbers when we collected the cells. In addition, the amount of
total RNA isolated from the cells was comparable between the
cells transfected with the DUX4 and insertless vectors. We selected
an earlier time point to collect cells in order to avoid profiling
dying or dead cells. The cell death likely will occur at a later time
point.
Previous studies showed that FSHD myoblasts and C2C12 cells
expressing DUX4 were more vulnerable to oxidative stress
[15,17–19,23–25,54], while another study of FSHD and control
myoblasts from relatives did not [31]. Our data showed that
ectopic DUX4 expression in RD cells caused the misregulation of
genes involved in the NRF2-mediated oxidative stress response
pathway, which is involved in combating oxidative stress.
Oxidative stress is caused when the rate of production of reactive
oxygen species such as free radicals and peroxides, exceeds their
rate of detoxification. Increases in levels of reactive oxygen species
can be very damaging to the cell and trigger apoptotic responses.
The NRF2 mediated oxidative stress response is the primary
pathway involved in combating oxidative stress through the action
of several detoxifying and anti-oxidant enzymes functioning in the
pathway. Misregulation of transcripts involved in the NRF2
mediated oxidative stress response pathway has been reported in
several FSHD studies [15,17–19,23–25,54]. Our study again
confirmed the link with DUX4. In addition, our data showed that
more changes that are pro-oxidative stress were induced by
DUX4. This pathway was also significant in C2C12 cells
expressing DUX4 but was not in top 3.
A novel finding of this study is the dramatic induction of UTS2
in response to ectopic DUX4 expression in both the RD and
C2C12 cells, which was also validated in the immortalized FHSD
myoblasts. UTS2 is a powerful vasoconstrictor and has also been
shown to be pro-angiogenic as evidenced by its ability to cause
increased proliferation of endothelial cells as well as increased
migration of vascular smooth muscle cells [55–59]. It has also been
recently shown associated with diabetic retinopathy and athero-
sclerosis [60]; therefore, its induction in response to DUX4
provides a potential explanation for the retinal vasculopathy
commonly observed in FSHD patients, who are found to exhibit
symptoms similar to those exhibited by patients of Coats’ disease,
wherein abnormal vessels develop behind retina [61,62]. Since the
molecular mechanism of these retinal defects remains yet
unknown, the up-regulation of UTS2 could potentially be involved
and worth for further investigation.
Interestingly, rhabdomyosarcoma cells have often been used to
study pharmacological properties of UTS2 and its receptors since
these cells endogenously express UTS2 receptors. Moreover,
UTS2 and its receptors have also been shown expressed at a
significantly greater level in human skeletal cells and tissues
compared with other organs such as pancreas, brain, liver, testis,
placenta, lung, kidney, thymus, prostate, small intestine, colon,
peripheral blood leukocytes, ovary and spleen. Our findings along
with the findings reported in these studies indicate that overex-
pression of UTS2 in skeletal muscle could be particularly
significant in contributing towards the skeletal muscular symptoms
in FSHD patients [63–66].
Our study suggests that DUX4 can contribute to FSHD
pathogenesis through several avenues including induction of
MYOD pathways, induction of immune and inflammatory
response, misregulation of genes involved in oxidative stress, and
induction of germline genes. Our study also reported a dramatic
induction of UTS2, a potent vasoconstrictor involved in angio-
genesis and also reported preferentially expressed in skeletal
muscle tissue in FSHD myoblasts, which could potentially explain
the vasculopathy and skeletal muscular symptoms observed in
FSHD patients. Furthermore, we showed that some of these
critical changes were not observed in mouse C2C12 myoblasts
while other changes overlapped, which suggest that a mouse
model carrying human DUX4 gene may not fully recapitulate the
human FSHD and needs to be evaluated carefully.
Supporting Information
Table S1 Transcripts regulated by DUX4 in RD cells.
RD cells transfected with DUX4 expression vector and insertless
vector (control) were expression profiled and fold-changes of
transcripts changed in response to ectopic DUX4 expression were
calculated relative to control. Welch’s t test was performed to
calculate the probabilities of significant gene expression changes
(p,0.05) along with multiple testing correction using Benjamini
Hochberg False Discovery Rate (5%).
(XLSX)
Table S2 Transcripts regulated by DUX4 in C2C12
cells. C2C12 cells transfected with DUX4 expression vector and
insertless vector (control) were expression profiled and fold-
changes of transcripts changed in response to ectopic DUX4
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expression were calculated relative to control. Welch’s t test was
performed to calculate the probabilities of significant gene
expression changes (p,0.05) along with multiple testing correction
using Benjamini Hochberg False Discovery Rate (5%).
(XLSX)
Table S3 Common transcripts regulated by DUX4 in
RD and C2C12 cells. Genespring GX 11.0 was used to identify
transcripts regulated by DUX4 in both RD and C2C12 cells
(p,0.05).
(XLSX)
Table S4 Transcripts functioning in immune response
pathways regulated by DUX4 in RD cells. Transcripts
identified in the top ranked canonical pathway regulated by
DUX4 in RD cells were identified through IPA.
(XLSX)
Table S5 Transcripts functioning in BMP signaling
pathway regulated by DUX4 in RD cells. Transcripts
functioning in BMP signaling pathway, the second ranked
canonical pathway regulated by DUX4 in RD cells, were
identified through IPA.
(XLSX)
Table S6 Transcripts functioning in NRF2 mediated
oxidative stress response pathway regulated by DUX4 in
RD cells. Transcripts functioning in NRF2 mediated oxidative
stress response pathway, the third ranked canonical pathway
regulated by DUX4 in RD cells, were identified through IPA.
(XLSX)
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